Combined potassium and calcium channel antagonistic activities as a basis for neutral frequency dependent increase in action potential duration: Comparison between BRL-32872 and azimilide

Cardiovascular Research

Volumn 37, Issue 1, 1998, Pages 130-140

  Bril, Antoine ^a   Forest, Marie Claire ^a   Cheval, Brigitte ^a   Faivre, Jean François ^a  

^a SmithKline Beecham Laboratoires P   (France)

Author keywords

Azimilide; BRL 32872; Calcium channel antagonists; Class III antiarrhythmic compounds; E 4031; Nitrendipine; Reverse frequency dependent increase in action potential duration; Ryanodine; Verapamil

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ANTIARRHYTHMIC AGENT; AZIMILIDE; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; N (3,4 DIMETHOXYPHENYL) N [3 [[2 (3,4 DIMETHOXYPHENYL)ETHYL]PROPYL] 4 NITROBENZAMIDE]; NITRENDIPINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM ION; RYANODINE; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL TISSUE; ARTICLE; CALCIUM CURRENT; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; GUINEA PIG; HEART MUSCLE POTENTIAL; HEART PAPILLARY MUSCLE; HEART STIMULATION; MALE; MICROELECTRODE; NONHUMAN; PRIORITY JOURNAL; SARCOLEMMA; SARCOPLASMIC RETICULUM;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BENZAMIDES; CALCIUM CHANNEL BLOCKERS; ELECTRIC STIMULATION; GUINEA PIGS; IMIDAZOLES; IMIDAZOLIDINES; MALE; MEMBRANE POTENTIALS; NITRENDIPINE; PAPILLARY MUSCLES; PIPERAZINES; PIPERIDINES; POTASSIUM CHANNEL BLOCKERS; PYRIDINES; RANDOM ALLOCATION; RYANODINE; VERAPAMIL;

EID: 0031913533     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00216-2     Document Type: Article

References (42)

1. Carmeliet E. Action potential duration and refractoriness. In: Singh BN, Wellens HJJ, Hiraoka M. editors. Electropharmacological control of cardiac arrhythmias. To delay conduction or to prolong refractoriness. New York: Futura Publishing Company, Inc, 1994:33-46.
2. Schmitt C., Brachmann J., Karch M., Waldecker B., Navarette L., Montero M., Beyer T., Kubler W. Reverse use-dependent effects of sotalol demonstrated by recording monophasic action potentials of the right ventricle. Am J Cardiol. 68:1991;1183-1187.
3. max. Br J Pharmacol. 103:1991;1568-1572.
4. K blocking drug, UK-68,798: Potent in guinea pig but no effect in rat myocardium. J Cardiovasc Pharmacol. 16:1990;401-410.
5. Sager P.T., Nademanee K., Antimisiaris M., Pacifico A., Pruitt C., Godfrey R., Singh B.N. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiological actions of sematilide HCl in humans. Circulation. 88:1993;1072-1082.
6. Kr blockers dofetilide, d-sotalol, E-4031, and MK-499. J Cardiovasc Pharmacol. 24:1994;199-208.
7. Todt H., Zojer N., Schütz W. Differential effect of dofetilide on ventricular repolarization during steady state and during restitution in vivo. J Cardiovasc Pharmacol. 24:1994;1010-1013.
8. Hondeghem L.M., Snyders D.J. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation. 81:1990;686-690.
9. Roden D.M. Early after-depolarizations and torsade de pointe: implications for the control of cardiac arrhythmias by prolonging repolarization. Eur Heart J. 14:1993;56-61.
10. Sloskey G.E. Amiodarone: a unique antiarrhythmic agent. Clin-Pharm. 2:1983;330-340.
11. Singh BN. Amiodarone: pharmacological, electrophysiological, and clinical profile of an unusual antiarrhythmic compound. In: Singh BN, Wellens HJJ, Hiraoka M, editors. Electropharmacological control of cardiac arrhythmias. To delay conduction or to prolong refractoriness? New York: Futura Publishing Company, Inc, 1994:497-522.
12. Sager P.T., Uppal P., Follmer C., Antimisiaris M., Pruitt C., Singh B.N. Frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation. 88:1993;1063-1071.
13. Bril A., Faivre J.F., Forest M.C., Cheval B., Gout B., Linee P., Ruffolo R.R. Jr., Poyser R.H. Electrophysiological effect of BRL 32872, a novel antiarrhythmic agent with potassium and calcium channel blocking properties, in guinea pig cardiac isolated preparations. J Pharmacol Exp Ther. 273:1995;1264-1272.
14. Fermini B., Jurkiewicz N.K., Jow B., Guinosso P.J.J., Baskin E.P., Lynch J.J. Jr., Salata J.J. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol. 26:1995;259-271.
15. Sanguinetti M.C., Jurkiewicz N.K. Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol. 96:1990;195-215.
16. Hachisu M., Pappano A.J. A comparative study of the blockade of calcium-dependent action potentials by verapamil, nifedipine and nimodipine in ventricular muscle. J Pharmacol Exp Ther. 255(1):1983;112-120.
17. 2+ release channel. J Biol Chem. 268:1993;13765-13768.
18. Ludbrook J. Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc Res. 28:1994;303-311.
19. Noble D. The initiation of the heartbeat. 2nd edn. Oxford: Clarendon Press, 1979:1-186.
20. Ohler A., Amos G.J., Wettwer E., Ravens U. Frequency-dependent effects of E-4031, almokalant, dofetilide and tedisamil on action potential duration: no evidence for "reverse use dependent" block. Naunyn-Schmiedebergs Arch Pharmacol. 349:1994;602-610.
21. + current by dofetilide. Circ Res. 72:1993;75-83.
22. + current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther. 262:1992;809-817.
23. Zhang Z.H., Boutjdir M., Brooks R., Chen L., El-Sherif N. Characterization of azimilide effects on ion currents of the repolarization phase. Biophys J. 68:1995;A111. Abstract.
24. KS in guinea pig cardiac myocytes. Biochem Biophys Res Commun. 202:1994;265-270.
25. Nattel S., Quantz M.A. Pharmacological response of quinidine induced early afterdepolarisations in canine cardiac Purkinje fibres: insights into underlying ionic mechanisms. Cardiovasc Res. 22:1988;808-817.
26. Hiromasa S., Coto H., Li Z.Y., Maldonado C., Kuperismith J. Dextrorotatory isomer of sotalol: electrophysiologic effects and interaction with verapamil. Am Heart J. 116:1988;1552-1557.
27. Bril A. Novel antiarrhythmic agents: from specific pharmacological tools to compounds with multiple cellular activity. Pharmacol Rev and Commun. 8:1996;9-17.
28. + channels. J Pharmacol Exp Ther. 234:1985;134-140.
29. + channel cloned from human heart. J Pharmacol Exp Ther. 44:1993;642-648.
30. K) of guinea pig ventricular myocytes. Biophys J. 66(2):1994;A325. Abstract.
31. Tohse N. Calcium-sensitive delayed rectifier potassium current in guinea pig ventricular cells. Am J Physiol. 258:1990;H1200-H1207.
32. + current in isolated membrane patches of guinea pig ventricular myocytes. Circ Res. 74:1994;96-104.
33. Gjini V., Korth M., Schreieck J., Weyerbrock S., Schomig A., Schmitt C. The "reverse-use dependence" of the Class III antiarrhythmics can be prevented by decreasing intracellular calcium. Pac Clin Electrophys. 19:1996;638. Abstract.
34. Abrahamsson C., Carlsson L., Duker G. Lidocaine and nisoldipine attenuate almokalant-induced dispersion of repolarization and early afterdepolarizations in vitro. J Cardiovasc Electrophysiol. 7:1996;1074-1081.
35. ++ overload. J Pharmacol Exp Ther. 279:1996;231-239.
36. Nishimura M., Follmer C.H., Singer D.H. Amiodarone blocks calcium current in single guinea pig ventricular myocytes. J Pharmacol Exp Ther. 251:1989;650-659.
37. Nokin P., Blondiaux J.P., Schaeffer P., Jungbluth L., Lugnier C. Amiodarone is a potent calmodulin antagonist. Naunyn-Schmiedebergs Arch Pharmacol. 339:1989;367-373.
38. Bril A., Gout B., Bonhomme M., Landais L., Faivre J.F., Linee P., Poyser R.H., Ruffolo R.R. Jr. Combined potassium and calcium channel blocking activities as the basis for antiarrhythmic properties with low proarrhythmic risk: experimental antiarrhythmic effect of BRL-32872. J Pharmacol Exp Ther. 276:1996;637-646.
39. Conder M.L., Hess T.A., Smith M.A., d'Alonzo A.J., McCullough J.R. The effects of NE-10064 on cardiac sodium channels. FASEB J. 8:1994;A609. Abstract.
40. Yao J.A., Tseng G.N. Azimilide (NE-10064) can prolong or shorten the action potential duration in canine ventricular myocytes: dependence on blockade of K, Ca and Na Channels. J Cardiovasc Electrophysiol. 8:1997;184-198.
41. Kosar E., Sharma P., Likittanasombat K., Krittayaphong R., Granett J., Egan J., Singh B.N., Nademanee K. Electrophysiologic and hemodynamic effects of a new combined Class III and Class IV antiarrhythmic agent: BRL 32872A. Pac Clin Electrophys. 20:1997;1142. Abstract.
42. Singh BN. Whither antiarrhythmic drugs? In: Singh BN, Wellens HJJ, Hiraoka M, editors. Electropharmacological control of cardiac arrhythmias. To delay conduction or to prolong refractoriness? Mount Kisco, New York: Futura Publishing Company, Inc, 1994:713-731.